Chordate Medical Holding has received approval for the listing of its preference share on Nasdaq First North Growth Market, with the first trading day set for Monday, March 17th, 2025.
In connection with Chordate Medical Holding’s recently completed rights issue, units consisting of common shares and preference shares were issued. Paid subscribed units (BTU) have now been converted into shares and preference shares. The number of issued preference shares amounts to 1,591,144 and will be traded under the ticker symbol CMH Pref with ISIN code SE0023848619.
The preference share is subject to a redemption clause and, under certain specified circumstances, entitles the holder to a dividend of up to SEK 12 per preference share, with priority over common shares. The full terms and conditions for the preference shares are outlined in the articles of association adopted at an extraordinary general meeting on January 28, 2025.
For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277
About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com
The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.
N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.